Page last updated: 2024-11-13

gal021

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GAL021: a calcium-activated potassium channel blocker; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57340959
SCHEMBL ID9105353
MeSH IDM000599974

Synonyms (27)

Synonym
SCHEMBL9105353
n-(4,6-bis-n-propylamino-[1,3,5]triazin-2-yl)-n,o-dimethyl-hydroxylamine
FJNLCHNQVJVCPY-UHFFFAOYSA-N
n-(4,6-bis-n-propylamino-[1,3,5]-triazin-2-yl)-n,o-dimethyl-hydroxylamine
n-(4,6-bis-n-propylamino [1,3,5]triazine-2-yl)-n,o-dimethyl-hydroxylamine
gal-021 ,
gal 021
gal021
C000593146
1380341-99-0
EX-A2726
AKOS030629509
HY-101422
CS-6340
6-(methoxy(methyl)amino)-n2,n4-dipropyl-1,3,5-triazine-2,4-diamine
BCP20772
Q20707338
ena-001
4rz4ogt40z ,
unii-4rz4ogt40z
1,3,5-triazine-2,4,6-triamine, n2-methoxy-n2-methyl-n4,n6-dipropyl-
2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine
MS-23587
2,4-diamine
6-(methoxy(methyl)amino)-n2,n4-dipropyl-1,3,5-triazine-
DTXSID601031220
n-(4,6-bis(propylamino)-1,3,5-triazin-2-yl)-n,o-dimethylhydroxylamine

Research Excerpts

Overview

GAL021 is a calcium-activated potassium (BKCa) channel blocker. Causes reversal of opioid-induced respiratory depression in animals. Has stimulatory effect on ventilation at the carotid bodies.

ExcerptReferenceRelevance
"GAL021 is a calcium-activated potassium (BKCa) channel blocker that causes reversal of opioid-induced respiratory depression in animals due to a stimulatory effect on ventilation at the carotid bodies."( Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers.
Dahan, A; Hay, J; McLeod, JF; Okkerse, P; Roozekrans, M; van der Schrier, R, 2014
)
1.35

Pharmacokinetics

ExcerptReferenceRelevance
" The analysis showed that (1) GAL021 interacts in a multiplicative fashion with alfentanil and GAL021, which predicts that GAL021 efficacy is reduced at low ventilation levels; (2) GAL021 has a rapid onset/offset with a blood-effect site equilibration half-life not different from zero; and (3) GAL021 displays ceiling in its efficacy to reverse OIRD."( Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers.
Dahan, A; McLeod, J; Olofsen, E; Peng, S; Roozekrans, M; van der Schrier, R; van Gerven, J, 2015
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.41 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]